Production of ginsenoside aglycone (protopanaxatriol) and male sterility of transgenic tobacco co-overexpressing three Panax ginseng genes: PgDDS, CYP716A47, and CYP716A53v2

  • Gwak, Yu Shin (Department of Forest Resources, College of Forest and Environmental Sciences, Kangwon National University) ;
  • Han, Jung Yeon (Department of Forest Resources, College of Forest and Environmental Sciences, Kangwon National University) ;
  • Choi, Yong Eui (Department of Forest Resources, College of Forest and Environmental Sciences, Kangwon National University)
  • Received : 2017.10.11
  • Accepted : 2018.02.08
  • Published : 2019.04.15


Background: Protopanaxatriol (PPT) is an aglycone of ginsenosides, which has high medicinal values. Production of PPT from natural ginseng plants requires artificial deglycosylation procedures of ginsenosides via enzymatic or physicochemical treatments. Metabolic engineering could be an efficient technology for production of ginsenoside sapogenin. For PPT biosynthesis in Panax ginseng, damarenediol-II synthase (PgDDS) and two cytochrome P450 enzymes (CYP716A47 and CYP716A53v2) are essentially required. Methods: Transgenic tobacco co-overexpressing P. ginseng PgDDS, CYP716A47, and CYP716A53v2 was constructed via Agrobacterium-mediated transformation. Results: Expression of the three introduced genes in transgenic tobacco lines was confirmed by Reverse transcription-polymerase chain reaction (RT-PCR). Analysis of liquid chromatography showed three new peaks, dammarenediol-II (DD), protopanaxadiol (PPD), and PPT, in leaves of transgenic tobacco. Transgenic tobacco (line 6) contained $2.8{\mu}g/g$ dry weight (DW), $7.3{\mu}g/g$ DW, and $11.6{\mu}g/g$ DW of PPT, PPD, and DD in leaves, respectively. Production of PPT was achieved via cell suspension culture and was highly affected by auxin treatment. The content of PPT in cell suspension was increased 37.25-fold compared with that of leaves of the transgenic tobacco. Transgenic tobacco was not able to set seeds because of microspore degeneration in anthers. Transmission electron microscopy analysis revealed that cells of phloem tissue situated in the center of the anther showed an abnormally condensed nuclei and degenerated mitochondria. Conclusion: We successfully achieved the production of PPT in transgenic tobacco. The possible factors deriving male sterility in transgenic tobacco are discussed.



Supported by : Rural Development Administration


  1. Christensen LP. Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutr Res 2009;55:1-99.
  2. Xiang YZ, Shang HC, Gao XM, Zhang BL. A comparison of the ancient use of ginseng in traditional Chinese medicine with modern pharmacological experiments and clinical trials. Phytother Res 2008;22:851-8.
  3. Leung KW, Wong AST. Pharmacology of ginsenosides: a literature review. Chin Med 2010;5:20.
  4. Nag SA, Qin JJ, Wang W, Wang MH, Wang H, Zhang R. Ginsenosides as anticancer agents: in vitro and in vivo activities, structure-activity relationships, and molecular mechanisms of action. Front Pharmacol 2012;3:25.
  5. Shibata S. Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci 2001;16:S28-37.
  6. Han JY, Kwon YS, Yang DC, Jung YR, Choi YE. Expression and RNA interferenceinduced silencing of the dammarenediol synthase gene in Panax ginseng. Plant Cell Physiol 2006;47:1653-62.
  7. Tansakul P, Shibuya M, Kushiro T, Ebizuka Y. Dammarenediol- II synthase, the first dedicated enzyme for ginsenoside biosynthesis, in Panax ginseng. FEBS Lett 2006;580:5143-9.
  8. Han JY, Kim HJ, Kwon YS, Choi YE. The cyt P450 enzyme CYP716A47 catalyzes the formation of protopanaxadiol from dammarenediol-II during ginsenoside biosynthesis in Panax ginseng. Plant Cell Physiol 2011;52:2062-73.
  9. Han JY, Hwang HS, Choi SW, Kim HJ, Choi YE. Cytochrome P450 CYP716A53v2 catalyzes the formation of protopanaxatriol from protopanaxadiol during ginsenoside biosynthesis in Panax ginseng. Plant Cell Physiol 2012;53:1535-45.
  10. Yan X, Fan Y, Wei W, Wang P, Liu Q, Wei Y, Zhang L, Zhao G, Yue J, Zhou Z. Production of bioactive ginsenoside compound K in metabolically engineered yeast. Cell Res 2014;24:770-3.
  11. Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos 2003;31:1065-71.
  12. Han BH, Park MH, Han YN, Woo LK, Sankawa U, Yahara S, Tanaka O. Degradation of ginseng saponins under mild acidic conditions. Planta Med 1982;44:146-9.
  13. Karikura M, Miyase T, Tanizawa H, Taniyama T, Takino Y. Studies on absorption, distribution, excretion and metabolism of ginseng saponins. VII. Comparison of the decomposition modes of ginsenoside-Rb1 and Rb2 in the digestive tract of rats. Chem Pharm Bull 1991;39:2357-61.
  14. Hasegawa H, Sung JH, Matsumiya S, Uchiyama M. Main ginseng saponin metabolites formed by intestinal bacteria. Planta Med 1996;62:453-7.
  15. Bae EA, Choo MK, Park EK, Park SY, Shin HY, Kim DH. Metabolism of ginsenoside Re by human intestinal bacteria and its related antiollergic activity. Biol Pharm Bull 2002;25:743-7.
  16. Hasegawa H, Sung JH, Benno Y. Role of human intestinal Prevotella oris in hydrolyzing ginseng saponins. Planta Med 1997;63:436-40.
  17. Jia W, Yan H, Bu X, Liu G, Zhao Y. Aglycone protopanaxadiol, a ginseng saponin, inhibits P-glycoprotein and sensitizes chemotherapy drugs on multidrug resistant cancer cells. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004;22(Suppl):9663.
  18. Popovich DG, Kitts DD. Ginsenosides 20(S)-protopanaxadiol and Rh2 reduce cell proliferation and increase sub-G1 cells in two cultured intestinal cell lines (Int-407 and Caco-2). Can J Physiol Pharmacol 2004;82:183-90.
  19. Bae EA, Han MJ, Kim EJ, Kim DH. Transformation of ginseng saponins to ginsenoside Rh2 by acids and human intestinal bacteria and biological activities of their transformants. Arch Pharm Res 2004;27:61-7.
  20. Hwang IG, Kim HY, Joung EM, Woo KS, Jeong JH, Yu KW, Lee JS, Jeong HS. Changes in ginsenosides and antioxidant activity of Korean ginseng (Panax ginseng C.A. Meyer) with heating temperature and pressure. Food Sci Biotechnol 2010;19:941-9.
  21. Cui JF, Garle M, Lund E, Bjorkhem I, Eneroth P. Analysis of ginsenosides by chromatography and mass spectrometry: release of 20 S-protopanaxadiol and 20 S-protopanaxatriol for quantitation. Anal Biochem 1993;210:411-7.
  22. Hasegawa H, Suzuki R, Nagaoka T, Tezuka Y, Kadota S, Saiki I. Prevention of growth and metastasis of murine melanoma through enhanced natural-killer cytotoxicity by fatty acid-conjugate of protopanaxatriol. Biol Pharm Bull 2002;25:861-6.
  23. Usami Y, Liu YN, Lin AS, Shibano M, Akiyama T, Itokawa H, Susan L, Bastow K, Kasai R, Lee KH. Antitumor agents. 261. 20(S)-protopanaxadiol and 20(S)-protopanaxatriol as antiangiogenic agents and total assignment of $^1H$ NMR spectra. J Nat Prod 2008;71:478-81.
  24. Kang SY, Schini-Kerth VB, Kim ND. Ginsenosides of the protopanaxatriol group cause endothelium-dependent relaxation in the rat arorta. Life Sci 1995;56:1577-86.
  25. Kwok HH, Ng WY, Yang MS, Mak NK, Wong RN, Yue PY. The ginsenoside protopanaxatriol protects endothelial cells from hydrogen peroxide-induced cell injury and cell death by modulating intracellular redox status. Free Radic Biol Med 2010;48:437-45.
  26. Hong SY, Kim JY, Ahn HY, Shin JH, Kwon O. Panax ginseng extract rich in ginsenoside protopanaxatriol attenuates blood pressure elevation in spontaneously hypertensive rats by affecting the akt-dependent phosphorylation of endothelial nitric oxide synthase. J Agric Food Chem 2012;60:3086-91.
  27. Attele AS, Zhou YP, Xie JT, Wu JA, Zhang L, Dey L, Pugh W, Rue PA, Polonsky KS, Yuan CS. Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes 2002;51:1851-8.
  28. Yuan HD, Kim JT, Kim SH, Chung SH. Ginseng and diabetes: the evidences from in vitro, animal and human studies. J Ginseng Res 2012;36:27-39.
  29. Hasegawa H. Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. J Pharmacol Sci 2004;95:153-7.
  30. Grunweller S, Schroeder E, Kesselmeier J. Biological activities of furostanol saponins from Nicotiana tabacum. Phytochemistry 1990;29:2485-90.
  31. Cheung HT. Constituents of Dipterocarpaceas resins. 2. Structure of dryobaranone from Dryobalanops aromatica. J Chem Soc 1968;21:2686-97.
  32. Spencer GF. Dammarenediol-II esters from Cacalia atriplicifolia L. seed oil. J Nat Prod 1981;44:166-8.
  33. Han JY, Wang HY, Choi YE. Production of dammarenediol-II triterpene in a cell suspension culture of transgenic tobacco. Plant Cell Rep 2014;33:225-33.
  34. Jensen K, Moller BL. Plant NADPH-cytochrome P450 oxidoreductases. Phytochemistry 2010;71:132-41.
  35. Kim IK, Roldao A, Siewers V, Nielsen J. A systems-level approach for metabolic engineering of yeast cell factories. FEMS Yeast Res 2012;12:228-48.
  36. Liu XB, Liu M, Tao XY, Zhang ZX, Wang FQ, Wei DZ. Metabolic engineering of Pichia pastoris for the production of dammarenediol-II. J Biotechnol 2015;216:47-55.
  37. Dai ZB, Liu Y, Zhang XN, Shi MY, Wang BB, Wang D, Huang LQ, Zhang XL. Metabolic engineering of Saccharomyces cerevisiae for production of ginsenosides. Metab Eng 2013;20:146-56.
  38. Thimmappa R, Geisler K, Louveau T, O'Maille P, Osbourn A. Triterpene biosynthesis in plants. Annu Rev Plant Biol 2014;65:225-57.
  39. Lee MH, Han JY, Kim HJ, Kim YS, Huh GH, Choi YE. Dammarenediol-II production confers TMV tolerance in transgenic tobacco expressing Panax ginseng dammarenediol-II synthase. Plant Cell Physiol 2012;53:173-82.
  40. Gwak YS, Han JY, Adhikari PB, Ahn CH, Choi YE. Heterologous production of a ginsenoside saponin (compound K) and its precursors in transgenic tobacco impairs the vegetative and reproductive growth. Planta 2017;245:1105-19.
  41. Alfermann AW, Petersen M. Natural product formation by plant cell biotechnology. Plant Cell Tiss Org Cult 1995;43:199-205.
  42. Ryder NS. Squalene epxodase as a target for the allylamines. Biochem Soc Trans 1991;19:774-7.
  43. Chappell J, Wolf F, Proulx J, Cuellar R, Saunders C. Is the reaction catalyzed by 3-hydroxy-3-methylglutaryl coenzyme A reductase a rate-limiting step for isoprenoid biosynthesis in plants? Plant Physiol 1995;109:1337-43.
  44. Lee MH, Jeong JH, Seo JW, Shin CG, Kim YS, In JG, Yang DC, Yi JS, Choi YE. Enhanced triterpene and phytosterol biosynthesis in Panax ginseng overexpressing squalene synthase gene. Plant Cell Physiol 2004;45:976-84.
  45. Chun JH, Adhikari PB, Park SB, Han JY, Choi YE. Production of the dammarene sapogenin (protopanaxadiol) in transgenic tobacco plants and cultured cells by heterologous expression of PgDDS and CYP716A47. Plant Cell Rep 2015;34:1551-60.
  46. Buckner B, Janick-Buckner D, Gray J. Cell-death mechanisms in maize. Trends in Plant Sci 1998;3:218-23.
  47. Reape TJ, McCabe PF. Apoptotic-like programmed cell death in plants. New Phytol 2008;180:13-26.
  48. Han JY, In JY, Kwon YS, Choi YE. Regulation of ginsenoside and phytosterol biosynthesis by RNA interferences of squalene epoxidase gene in Panax ginseng. Phytochemistry 2010;71:36-46.
  49. Kim TD, Han JY, Huh GH, Choi YE. Expression and functional characterization of three squalene synthase genes associated with saponin biosynthesis in Panax ginseng. Plant Cell Physiol 2011;52:125-37.
  50. Gottlieb RA. Cytochrome P450: major player in reperfusion injury. Arch Biochem Biophys 2003;420:262-7.
  51. Zangar RC, Davydov DR, Verma S. Mechanisms that regulate production of reactive oxygen species by cytochrome P450. Toxicol Appl Pharmacol 2004;199:316-31.